Search: onr:"swepub:oai:gup.ub.gu.se/223599" >
Clinical benefits o...
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial
-
Girerd, N. (author)
-
Collier, T. (author)
-
Pocock, S. (author)
-
show more...
-
Krum, H. (author)
-
McMurray, J. J. (author)
-
- Swedberg, Karl, 1944 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
van Veldhuisen, D. J. (author)
-
Vincent, J. (author)
-
Pitt, B. (author)
-
Zannad, F. (author)
-
show less...
-
(creator_code:org_t)
- 2015-06-20
- 2015
- English.
-
In: European Heart Journal. - : Oxford University Press (OUP). - 0195-668X .- 1522-9645. ; 36:34, s. 2310-2317
- Related links:
-
https://academic.oup...
-
show more...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Aims Cardiovascular hospitalization (CVH) in patients with heart failure (HF) is associated with a high post-discharge rate of early re-admission and CV death. Eplerenone might be effective in reducing the incidence of these adverse clinical outcomes during this period. Methods and results The EMPHASIS-HF trial compared eplerenone with placebo added to standard therapy in 2737 patients with New York Heart Association class II HF and left ventricular ejection fraction <= 35%. We conducted a post hoc analysis in the 2338 patients randomized within 180 days of a CVH. The interaction between the time from the qualifying CVH to randomization and the primary outcome of CV death or hospitalization for HF (HHF), as well as other secondary outcomes, was assessed in Cox survival models. Most of the qualifying CVHs were HHF (N = 1496, 64.0%), acute coronary syndromes (N = 390, 16.7%), and arrhythmias (N = 197, 7.2%). The median time of study drug initiation from qualifying CVH was 42 days. The relative rate reductions in CV death/HHF, HHF, and all-cause mortality were similar (P for interaction = 0.65, 0.44, and 0.40, respectively) whether the treatment was initiated <42 or 42+ days after qualifying CVH. Absolute rate reductions were -5.61 [-8.67, -2.55] events per 100 patient x years in the <42 days group and -3.58 [-6.37, -0.79] in the 42+ days group. The adverse effects of eplerenone were also unaffected by the time from the qualifying CVH. Conclusion Eplerenone is safe, improves survival, and may prevent re-admission when initiated soon after a hospitalization for HF or acute coronary syndromes in patients with systolic HF and mild symptoms.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Keyword
- Eplerenone
- Systolic heart failure
- Hospitalization
- Timing
- Treatment effect
- EMPHASIS-HF
- ALDOSTERONE ANTAGONISTS
- GUIDELINES
- ASSOCIATION
- THERAPY
- IMPACT
- HYPERKALEMIA
- PERSPECTIVES
- PREDICTORS
- INHIBITORS
- MORTALITY
- Cardiac & Cardiovascular Systems
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Girerd, N.
-
Collier, T.
-
Pocock, S.
-
Krum, H.
-
McMurray, J. J.
-
Swedberg, Karl, ...
-
show more...
-
van Veldhuisen, ...
-
Vincent, J.
-
Pitt, B.
-
Zannad, F.
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
European Heart J ...
- By the university
-
University of Gothenburg